• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Tafamidis attenuates the decline of cardiac function in patients with transthyretin amyloid cardiomyopathy

byYasin AvciandYuchen Dai
December 31, 2023
in Cardiology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) managed with tafamidis showed decreased worsening in left ventricular (LV) systolic and diastolic function over 30 months compared to the placebo group.

2. Approximately half of the subjects enrolled in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) exhibited various levels of diminished left ventricular ejection fraction (LVEF), underscoring the importance of considering ATTR-CM as a potential diagnosis in individuals with heart failure, irrespective of the underlying LVEF.

Evidence Rating Level: 1 (Excellent)

Study Rundown: ATTR-CM is a fatal condition resulting from the accumulation of transthyretin amyloid fibrils in the myocardium, leading to cardiomyopathy and heart failure symptoms. Untreated ATTR-CM has a poor prognosis, the disease manifests with increased ventricular wall thickness and diastolic dysfunction due to amyloid deposits. In the ATTR-ACT, tafamidis demonstrated significant benefits, reducing mortality, cardiovascular-related hospitalizations, and the decline in functional capacity and quality of life compared to placebo. Despite recognized clinical benefits, the impact of tafamidis on echocardiographic parameters measuring cardiac function remains incompletely characterized, with recent single-center studies suggesting a potential attenuation of cardiac function decline in patients treated with tafamidis compared to patients who have never taken the drug. The goal of this post hoc analysis of the ATTR-ACT was to elucidate the underlying factors contributing to improved survival with tafamidis, administered at the approved dose for ATTR-CM (80 mg). This was done by evaluating the echocardiographic measures recognized as prognostic factors for mortality in ATTR-CM of both the drug group and placebo group. They found that over 30 months, patients with ATTR-CM treated with tafamidis exhibited a reduction in the deterioration of LV and diastolic function compared to the placebo group. One strength of this study was its utilization of a core laboratory to ensure a standardized evaluation of echocardiographic data, enhancing the reliability and consistency of the assessments across the study participants and contributing to the overall robustness of the research. In conclusion, these clinical observations underscore the importance of early diagnosis and intervention in individuals with ATTR-CM to mitigate the progressive deterioration of cardiac function.

Click to read the study in JAMA Cardiology

Relevant Reading: Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

RELATED REPORTS

Patisiran prevents functional decline in patients with cardiac amyloidosis

#VisualAbstract: Antibody NI006 for treatment of transthyretin amyloid cardiomyopathy caused no serious adverse events

Antibody NI006 for treatment of transthyretin amyloid cardiomyopathy caused no serious adverse events

In-Depth [randomized controlled trial]: This study is a post hoc analysis of the ATTR-ACT, an international, multicenter, double-blind, placebo-controlled phase 3 randomized clinical trial of tafamidis for ATTR-CM conducted between December 2013 to February 2018. Patients aged 18 to 90 with biopsy-confirmed ATTRv-CM (hereditary) or ATTRwt-CM (wild type), a history of heart failure, and end-diastolic interventricular septal wall thickness of 12mm or greater were randomized 2:1:2 to receive once-daily oral tafamidis meglumine (80mg), tafamidis meglumine (20mg), or matching placebo for 30 months. The primary analysis involved comparing alterations in LVEF, LV stroke volume (LVSV), LV global longitudinal strain (LVGLS), and septal and lateral E/e’ at baseline, 6 months, 18 months, and 30 months among the tafamidis (80mg) and placebo groups. Additionally, changes in regional measures of LV longitudinal, circumferential, and radial strain, as well as left atrial diameter from baseline to month 30, were examined between the treatment groups. The longitudinal analyses specifically focused on patients receiving tafamidis (80mg), as it represents the approved dose for ATTR-CM. Among 436 patients with available echocardiographic data, 50.5% had heart failure with preserved LV ejection fraction, 27.3% had mildly reduced, and 22.2% had reduced ejection fraction. Over 30 months, individuals receiving tafamidis (80mg) experienced less significant deterioration in four echocardiographic measures compared to those on placebo (176 patients vs. 177 patients): LVSV (least squares mean difference: 7.02 mL; 95% CI, 2.55-11.49; P = 0.002), LVGLS (−1.02%; 95% CI, −1.73 to −0.31; P = 0.005), septal E/e′ (−3.11; 95% CI, −5.50 to −0.72; P = 0.01), and lateral E/e′ (−2.35; 95% CI, −4.01 to −0.69; P = 0.006). A decrease in LVEF became evident starting from month 6 with the placebo group, while there was minimal decline observed with tafamidis (80mg) until month 30. There were no significant interactions between the impact of tafamidis (80mg) and baseline LVEF across various outcomes, including all-cause mortality (P = 0.40), cardiovascular-related hospitalizations (P = 0.35), and changes in specific echocardiographic parameters.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ATTR amyloidosisATTR-CMtafamidistransthyretin amyloidosis (ATTR amyloidosis)
Previous Post

Profiling levels of cognitive functioning at 6 months following traumatic brain injury

Next Post

Rates of opioid agonist therapy initiation increasing after hospital visits for opioid toxicity in Ontario, Canada

RelatedReports

Image-guided percutaneous drainage of pericardial effusions is safe and effective
Cardiology

Patisiran prevents functional decline in patients with cardiac amyloidosis

December 8, 2023
#VisualAbstract: Antibody NI006 for treatment of transthyretin amyloid cardiomyopathy caused no serious adverse events
StudyGraphics

#VisualAbstract: Antibody NI006 for treatment of transthyretin amyloid cardiomyopathy caused no serious adverse events

September 14, 2023
Antidepressant may reduce mental stress-induced myocardial ischemia (REMIT Trial)
Cardiology

Antibody NI006 for treatment of transthyretin amyloid cardiomyopathy caused no serious adverse events

September 8, 2023
Patisiran therapy reduces ventricular myocardial strain in hereditary transthyretin amyloidosis
Cardiology

Simple score developed to predict increased risk of transthyretin amyloid cardiomyopathy in patients with heart failure with preserved ejection fraction

September 17, 2022
Next Post
Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use

Rates of opioid agonist therapy initiation increasing after hospital visits for opioid toxicity in Ontario, Canada

American Academy of Pediatrics recommends standards for adverse event disclosures

2 Minute Medicine Rewind January 1, 2024

Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity

Education level is associated with prenatal antidepressant continuation in pregnant women

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.